 |
| |
| May-29-18 | Downgrade |
HSBC Securities |
Buy → Hold |
|
|
| May-25-18 | Upgrade |
Credit Suisse |
Underperform → Neutral |
|
|
| Jan-25-18 | Reiterated |
Leerink Partners |
Outperform |
$93 → $100 |
|
| Dec-06-17 | Downgrade |
BofA/Merrill |
Neutral → Underperform |
|
|
| Jul-26-17 | Upgrade |
Morgan Stanley |
Underweight → Overweight |
|
|
| Jul-05-17 | Downgrade |
Credit Suisse |
Neutral → Underperform |
|
|
| Mar-09-17 | Initiated |
Liberum |
Buy |
|
|
| Mar-08-17 | Upgrade |
Societe Generale |
Hold → Buy |
|
|
| Mar-07-17 | Downgrade |
Exane BNP Paribas |
Neutral → Underperform |
|
|
| Jan-11-17 | Downgrade |
Credit Suisse |
Outperform → Neutral |
|
|
| Nov-10-16 | Upgrade |
Argus |
Hold → Buy |
|
|
| Oct-10-16 | Reiterated |
Chardan Capital Markets |
Buy |
$95 → $92 |
|
| Sep-20-16 | Initiated |
Chardan Capital Markets |
Buy |
$95 |
|
| Apr-12-16 | Downgrade |
Morgan Stanley |
Equal-Weight → Underweight |
|
|
| Mar-23-16 | Downgrade |
Leerink Partners |
Outperform → Mkt Perform |
|
|
| Jun-22-15 | Upgrade |
Bryan Garnier |
Neutral → Buy |
|
|
| Nov-16-09 | Initiated |
Deutsche Securities |
Buy |
|
|
| Nov-12-09 | Initiated |
Barclays Capital |
Underweight |
$48 |
|
| Sep-30-09 | Upgrade |
Citigroup |
Hold → Buy |
|
|
| Sep-15-09 | Upgrade |
Jefferies & Co |
Hold → Buy |
|
|
|
|
| Aug-16-18 01:25PM | FDA approves first rival generic EpiPen, sending Teva shares up 6% MarketWatch |
| 07:00AM | Market Morning: Gene Therapy Deregulation, Amazon to the Movies, SEC On Musks Tail Market Exclusive |
| Aug-14-18 02:24PM | Three expansions, 923 jobs: Durham County approves incentives packages American City Business Journals |
| 01:28PM | Array BioPharma Inc. (ARRY) Q4 2018 Earnings Conference Call Transcript Motley Fool |
| 09:49AM | Regeneron's 12-Week Eylea Dose Gets CRL From FDA for Wet AMD Zacks |
| 05:47AM | Novartis recruits new compliance head from Siemens after ethics stumbles Reuters |
| Aug-13-18 02:52PM | Mixed Reviews For Allakos As Sell-Side Starts Coverage Of Biotech Benzinga |
| Aug-07-18 04:50PM | This Midcap Biotech Popped Nearly 20% On Hope In Cancer, Inflammation Investor's Business Daily |
| Aug-06-18 04:15PM | Can These Biotech Companies Catch Novartis, Gilead In CAR-T? Investor's Business Daily |
| 04:08PM | Does Bausch Face A Reckoning? 5 Key Issues To Look For In Its Earnings Investor's Business Daily |
| 09:09AM | The Zacks Analyst Blog Highlights: Pfizer, Bristol-Myers, Sanofi, Glaxo and Novartis Zacks |
| 08:56AM | Why Novartis Stock Gained 11% in July Motley Fool |
| Aug-05-18 07:42PM | How China Is Evolving From a Maker of Copycat Medicines Into a Producer of Complex Drugs The Wall Street Journal |
| 08:00AM | J&J Bets on Chinese Startup That Uses Llama DNA to Fight Cancer The Wall Street Journal |
| Aug-03-18 04:00PM | Teva Chief Says Generic Prices Are Improving Will Its Stock Also Do So? Investor's Business Daily |
| 02:46PM | Avoid Treating Biogen Like a Speculative Drug Stock InvestorPlace |
| 12:07PM | Aduro (ADRO) Q2 Loss Narrower Than Expected, Revenues Miss Zacks |
| Aug-02-18 04:43PM | Healthcare Bulls Get a Second Dose of Earnings-Driven Profits TheStreet.com |
| 11:47AM | Conatus' (CNAT) Q2 Loss Narrows, Revenues Lag Marginally Zacks |
| Aug-01-18 01:45PM | More drugmakers build Brexit stockpiles as EU agency faces exodus Reuters |
| 09:38AM | Sanofi, Novartis latest to stockpile drugs in case of no-deal Brexit Reuters |
| 09:35AM | Sanofi, Novartis latest to stockpile drugs in case of no-deal Brexit Reuters |
| 09:34AM | Biotech Stock Roundup: Celgene, Amgen, Vertex Impress in Q2, Gilead's CEO to Exit Zacks |
| Jul-31-18 12:15PM | 3 Biotech Stocks in Focus on Tuesday ACCESSWIRE |
| Jul-27-18 04:34PM | Antibiotics market wipes out 80 jobs at Peninsula company a month after its 1st drug approval American City Business Journals |
| 01:00PM | 1 week until the deadline for Disrupt SF 2018s Hackathon + new sponsor prizes TechCrunch |
| 09:23AM | Amgen (AMGN) Q2 Earnings & Sales Beat Estimates, View Up Zacks |
| Jul-26-18 07:30AM | Initiating Free Research Reports on Pfizer and Three Other Drug Makers Equities ACCESSWIRE |
| Jul-25-18 06:02PM | Why AnaptysBio Rose 10.5% Today Motley Fool |
| 05:01PM | Gilead's Earnings Fail to Impress TheStreet.com |
| 09:15AM | Glaxo (GSK) Beats on both Earnings and Revenue in Q2 Zacks |
| Jul-24-18 11:54AM | Novartis's Cultural Revolution Will Be AI-Enabled and Desk-Free Bloomberg |
| Jul-23-18 04:20PM | What's in the Cards for Glaxo (GSK) This Earnings Season? Zacks |
| 10:45AM | Tilrays IPO Looks Badly Overpriced And It Might Not Matter InvestorPlace |
| 09:26AM | Should GlaxoSmithKline Break Up? Motley Fool |
| 09:01AM | The Zacks Analyst Blog Highlights: Microsoft, Novartis, Goldman Sachs, Starbucks and General Motors Zacks |
| Jul-21-18 08:44AM | Canaccord Previews Biotech Catalysts In The Second Half: Neurological Drugs In Focus Benzinga |
| Jul-20-18 05:43PM | Pfizer gets FDA approval for drug similar to Amgen's Neupogen MarketWatch |
| 11:11AM | Swiss, German drugmakers join U.S. price freeze Reuters |
| 11:02AM | Top Research Reports for Microsoft, Novartis & Goldman Sachs Zacks |
| 10:48AM | Swiss, German drugmakers join U.S. price freeze Reuters |
| 08:59AM | Pharma Stock Roundup: JNJ & NVS' Q2 Earnings, FDA Approvals Zacks |
| 07:30AM | Three Key Takeaways From Healthcare Earnings Season TheStreet.com |
| 07:00AM | Free Post Earnings Research Report: Novartis Net Sales Jumped 7%; Non-GAAP EPS Advanced 6% ACCESSWIRE |
| Jul-19-18 06:52PM | Novartis wont raise drug prices in US Fox Business Videos |
| 06:43PM | Novartis' (NVS) Kisqali Gets FDA Nod for Label Expansion Zacks |
| 11:31AM | Novartis Sues to Block Generic Sales of Top Drug Gilenya for MS Bloomberg |
| 09:14AM | Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut Benzinga |
| 08:33AM | [$$] Novartis, MorphoSys and Galapagos Shares Rise on Drug Deal The Wall Street Journal |
| 06:52AM | Trump thanks Novartis, Pfizer for not raising drug prices Reuters |
| 02:29AM | Novartis to Pay as Much as $1 Billion for Rights to Skin Drug Bloomberg |
| 02:25AM | Novartis to pay 95 mln euros to Galapagos, MorphoSys for skin drug Reuters |
| Jul-18-18 08:00PM | [$$] Novartis Wont Raise U.S. Drug Prices This Year The Wall Street Journal |
| 04:27PM | Novartis Q2 Earnings Miss, Sales Top on Cosentyx, Entresto Zacks |
| 03:07PM | 5 Big Biotech Stories to Watch TheStreet.com |
| 12:54PM | Novartis hints at 2018 outlook hike despite drug price freeze Reuters |
| 12:32PM | Novartis Earnings: 'A Focused Company Wins,' Says CEO Barrons.com |
| 11:08AM | Novartis AG (NVS) Q2 2018 Earnings Conference Call Transcript Motley Fool |
| 10:50AM | [$$] Novartis Won't Raise U.S. Drug Prices This Year The Wall Street Journal |
| 08:42AM | Benzinga's Daily Biotech Pulse: Novartis Earnings, J&J's HIV Combo Clears FDA Hurdle, Cara To Offer Shares Benzinga |
| 06:53AM | Novartis joins Pfizer in halting U.S. drug price hikes Reuters |
| 05:02AM | Novartis: 2Q Earnings Snapshot Associated Press |
| 04:50AM | Novartis CEO Says It's `Prudent' to Pull Back From Further Price Increases Bloomberg Video |
| 04:50AM | Novartis CEO Says It's `Prudent' to Pull Back From Further Price Increases Bloomberg |
| 04:20AM | Novartis puts brakes on price hikes, bowing to U.S. pressure Reuters |
| 03:16AM | Swiss drugs giant Novartis says profit up as spinoff looms Associated Press |
| 02:36AM | Novartis Joins Pfizer in Holding Line on Drug Prices in U.S. Bloomberg |
| 02:36AM | Novartis CEO Says Drugmaker Won't Raise U.S. Prices This Year Bloomberg |
| 02:11AM | [$$] Novartis Confirms Outlook The Wall Street Journal |
| 01:21AM | Novartis Blockbuster Drug Rebounds, Easing Generics Pressure Bloomberg |
| Jul-17-18 10:49PM | [$$] Chinese Hit Movie Dying to Survive Injects Urgency in Drug-Price Push The Wall Street Journal |
| 10:13PM | Novartis (NVS) Stock Flat Ahead of Earnings: What To Watch Zacks |
| 04:04PM | Earnings Outlook For Novartis Benzinga |
| 12:33PM | GlaxoSmithKline Is More Than Just a 5% Dividend Income Play InvestorPlace |
| Jul-16-18 08:15AM | Is a Surprise in the Cards for Novartis in Q2 Earnings? Zacks |
| 08:01AM | The Zacks Analyst Blog Highlights: Johnson & Johnson, Novartis, UnitedHealth and Microsoft Zacks |
| Jul-13-18 08:04PM | [$$] Novartis Played Down Ties to Trump Lawyer Michael Cohen, Report Says The Wall Street Journal |
| 04:49PM | [$$] Novartis Communicated With Trump's Lawyer for Months, Report Says The Wall Street Journal |
| 03:09PM | Novartis Looks to Exit Antibacterial, Antiviral Program Zacks |
| 01:35PM | Dems: Novartis deal with Cohen sought access to policymakers Associated Press |
| 11:47AM | Novartis Account of Cohen Connection Assailed by U.S. Senators Bloomberg |
| 09:45AM | AT&T failed to provide requested documents to Senate probe of payments made to Michael Cohen MarketWatch |
| 09:21AM | Novartis disputes U.S. senators' report on Cohen contract Reuters |
| 09:16AM | Novartis disputes U.S. senators' report on Cohen contract Reuters |
| 08:43AM | JNJ vs. NVS: Which Stock is Better Pre Q1 Earnings? Zacks |
| 08:36AM | Novartis disputes U.S. senators' report over Cohen contract Reuters |
| 08:33AM | Cohen's Novartis Work Was Broader Than Reported, Democrats Say Bloomberg |
| 08:33AM | Cohen Pitched Novartis Russia-Tied Investment, Democrats Say Bloomberg |
| 08:15AM | Better Know Biotech: Regenxbio Inc. Motley Fool |
| 12:00AM | Superbugs Win Another Round as Big Pharma Leaves Antibiotics Bloomberg |
| Jul-12-18 09:05PM | [$$] Democrats allege Trump lawyer had broad contacts with Novartis Financial Times |
| 08:59AM | 3 Gene Therapy Stocks Investors Can Bet on in Rest of 2018 Zacks |
| 07:15AM | Novartis launches the Galaxies of Hope app, a digital experience for the Neuroendocrine Tumor (NET) cancer community PR Newswire |
| Jul-11-18 05:53PM | Novartis Exits Antibiotics Research, Cuts 140 Jobs in Bay Area Bloomberg |
| 05:49PM | Once with lofty plans, Novartis now closing East Bay unit, cutting 140 jobs American City Business Journals |
| 01:00PM | Removing the Hidden Obstacle Holding Back New Cancer Therapies Bloomberg |
| 04:47AM | Moody's: European pharma sector earnings poised to rise into 2019 as new drugs come to market Moody's |
| Jul-10-18 04:47PM | Kate Warne- Investment Strategist Edward Jones Yahoo Finance Video |
| 02:46PM | Drugmakers Cancel Price Hikes After California Law Takes Effect Bloomberg |
| Jul-09-18 08:58AM | [$$] China vows to accelerate cancer drug price cuts Financial Times |
|
|
|
|
| Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. The company's Innovative Medicines segment offers patented prescription medicines to enhance health outcomes for patients and health-care providers. This segment also commercializes products in the areas of oncology and rare diseases, ophthalmology, immunology and dermatology, neuroscience, respiratory, cardio-metabolic, and established medicines. The Sandoz segment provides active ingredients and finished dosage forms of pharmaceuticals in the areas of cardiovascular, central nervous system, dermatology, gastrointestinal and hormonal therapies, metabolism, oncology, ophthalmic, pain, and respiratory; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. The Alcon segment offers eye care products, such as eye care devices for cataract, retinal, glaucoma, and refractive surgery, as well as intraocular lenses to treat cataracts and refractive errors; viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery; and contact lenses, as well as contact lens care products, including multi-purpose and hydrogen-peroxide based solutions, rewetting drops, and daily protein removers. Novartis AG has collaboration agreements with Xencor; Surface Oncology; Intellia Therapeutics; Caribou Biosciences; Bristol-Myers Squibb; IBM Watson Health; Amgen; Allergan plc; Science 37, Inc.; Bill & Melinda Gates Foundation; and PEAR Therapeutics. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland. |
|
| Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
| Novartis Bioventures Ltd | 10% Owner | Aug 13 | Sale | 2.36 | 1,600 | 3,776 | 2,440,713 | Aug 14 05:05 PM | | Novartis Bioventures Ltd | 10% Owner | Aug 10 | Sale | 2.44 | 5,615 | 13,701 | 2,442,313 | Aug 14 05:05 PM | | Novartis Bioventures Ltd | 10% Owner | Aug 09 | Sale | 2.48 | 235 | 583 | 2,447,928 | Aug 10 04:29 PM | | Novartis Bioventures Ltd | 10% Owner | Aug 08 | Sale | 2.78 | 1,000 | 2,780 | 2,448,163 | Aug 10 04:29 PM | | Novartis Bioventures Ltd | 10% Owner | Aug 07 | Sale | 2.97 | 1,739 | 5,165 | 2,449,163 | Aug 08 04:21 PM | | Novartis Bioventures Ltd | 10% Owner | Aug 06 | Sale | 3.02 | 2,942 | 8,885 | 2,450,902 | Aug 08 04:21 PM | | Novartis Bioventures Ltd | 10% Owner | Aug 02 | Sale | 3.33 | 4,702 | 15,658 | 2,453,844 | Aug 06 04:22 PM | | Novartis Bioventures Ltd | 10% Owner | Aug 01 | Sale | 3.22 | 8,181 | 26,343 | 2,458,546 | Aug 02 04:33 PM | | Novartis Bioventures Ltd | 10% Owner | Jul 31 | Sale | 3.07 | 4,500 | 13,815 | 2,466,727 | Aug 02 04:33 PM | | Novartis Bioventures Ltd | 10% Owner | Jul 30 | Sale | 3.27 | 2,000 | 6,540 | 2,471,227 | Jul 31 04:16 PM | | Novartis Bioventures Ltd | 10% Owner | Jul 27 | Sale | 3.38 | 6,458 | 21,828 | 2,473,227 | Jul 31 04:16 PM | | Novartis Bioventures Ltd | 10% Owner | Jul 26 | Sale | 3.63 | 7,937 | 28,811 | 2,479,685 | Jul 27 04:21 PM | | Novartis Bioventures Ltd | 10% Owner | Jul 25 | Sale | 3.84 | 12,460 | 47,846 | 2,487,622 | Jul 27 04:21 PM | | Novartis Bioventures Ltd | 10% Owner | Jul 24 | Sale | 4.11 | 700 | 2,877 | 2,500,082 | Jul 25 04:35 PM | | Novartis Bioventures Ltd | 10% Owner | Jul 23 | Sale | 4.25 | 30,600 | 130,050 | 2,500,782 | Jul 25 04:35 PM | | Novartis Bioventures Ltd | 10% Owner | Jul 17 | Sale | 4.71 | 12,500 | 58,875 | 2,531,382 | Jul 18 04:17 PM | | Novartis Bioventures Ltd | 10% Owner | Jul 16 | Sale | 5.15 | 300 | 1,545 | 2,543,882 | Jul 18 04:17 PM | | Novartis Institutes for BioMed | 10% Owner | Apr 23 | Buy | 15.00 | 766,666 | 11,499,990 | 3,948,482 | Apr 23 04:43 PM |
|
|
|
|
|
|
